Kalra P S, Dube M G, Xu B, Farmerie W G, Kalra S P
Department of Physiology, University of Florida College of Medicine, Gainesville 32610, USA.
Physiol Behav. 1998 Mar;63(5):829-35. doi: 10.1016/s0031-9384(97)00545-3.
Hyperphagia and obesity can be experimentally induced in rodents by microinjection of 6-hydroxydopamine (6-OHDA) into the ventral noradrenergic bundle (VNAB) to interrupt efferent catecholaminergic pathways to the hypothalamus. Since hypothalamic neuropeptide Y (NPY) is implicated in the control of ingestive behavior, we evaluated hypothalamic NPY activity in this model of obesity. Adult male rats injected bilaterally with 12 microg of 6-OHDA in the VNAB displayed an enhanced rate of body weight gain and selective dark-phase hyperphagia that started at about 10 days postinjection and persisted for the entire duration of the experiment. NPY gene expression, assessed by ribonuclease protection assay, was significantly higher in the hypothalami of 6-OHDA-treated hyperphagic rats during the dark phase (p < 0.01 vs. levels during the light phase and in control, vehicle-injected rats). We also evaluated gene expression of NPY Y and Y5 receptors, receptor subtypes reported to mediate NPY-induced feeding. The dark-phase increase in NPY mRNA was accompanied by the concomitant upregulation of NPY Y5R gene expression, but not of Y1R mRNA levels. Leptin, the peripheral hormone secreted by adipocytes, is believed to maintain body weight and inhibit food intake, most likely by suppressing hypothalamic NPY activity. Evaluation of leptin gene expression in the epididymal fat revealed that the upregulation of leptin mRNA noted during the dark phase in control rats did not occur in 6-OHDA-treated rats. These observations implied that the normal restraint on NPY and feeding exercised by leptin in control rats may be abrogated in 6-OHDA-treated hyperphagic rats due to insufficient levels of leptin. If so, administration of leptin should inhibit food intake in these rats. Indeed, injection of leptin (2 mg/kg, intraperitoneally (i.p.)) on 2 consecutive days reduced 24-h food intake by 25% and significantly reduced body weight. These results suggest that the nocturnal hyperphagia and resultant obesity induced by 6-OHDA injected into the VNAB may be attributed to leptin deficiency concomitant with increased hypothalamic NPY.
通过向腹侧去甲肾上腺素能束(VNAB)微量注射6-羟基多巴胺(6-OHDA)以中断至下丘脑的传出儿茶酚胺能通路,可在啮齿动物中实验性诱导出摄食过量和肥胖。由于下丘脑神经肽Y(NPY)与摄食行为的控制有关,我们在这种肥胖模型中评估了下丘脑NPY的活性。双侧在VNAB中注射12微克6-OHDA的成年雄性大鼠体重增加速率加快,且在注射后约10天开始出现选择性暗期摄食过量,并在整个实验期间持续存在。通过核糖核酸酶保护试验评估,在暗期,6-OHDA处理的摄食过量大鼠下丘脑的NPY基因表达显著更高(与光期水平及注射溶剂的对照大鼠相比,p < 0.01)。我们还评估了NPY Y和Y5受体的基因表达,据报道这两种受体亚型介导NPY诱导的进食。NPY mRNA在暗期的增加伴随着NPY Y5R基因表达的同时上调,但Y1R mRNA水平未上调。脂肪细胞分泌的外周激素瘦素被认为可维持体重并抑制食物摄入,最有可能是通过抑制下丘脑NPY活性来实现。对附睾脂肪中瘦素基因表达的评估显示,对照大鼠暗期出现的瘦素mRNA上调在6-OHDA处理的大鼠中未出现。这些观察结果表明,由于瘦素水平不足,对照大鼠中瘦素对NPY和进食的正常抑制作用在6-OHDA处理的摄食过量大鼠中可能被消除。如果是这样,给予瘦素应能抑制这些大鼠的食物摄入。事实上,连续两天腹腔注射(i.p.)瘦素(2毫克/千克)使24小时食物摄入量减少了25%,并显著降低了体重。这些结果表明,向VNAB注射6-OHDA诱导的夜间摄食过量及由此导致的肥胖可能归因于瘦素缺乏以及下丘脑NPY增加。